Catalyst Pharma director O'Keeffe to retire; not standing for reelection at 2025 meeting

CATALYST PHARMACEUTICALS, INC.

Charles B. O'Keeffe, 85, will not stand for reelection at the 2025 annual meeting; term ends at that meeting.
O'Keeffe has served as independent director since 2004, currently Lead Independent Director.
Retirement not due to any disagreement with company on operations, policies, or practices.
Corporate Governance Committee will hire a recruitment firm to search for a replacement director.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Charles B. O’Keeffe

Lead Independent Director

CPRX · CATALYST PHARMACEUTICALS, INC.

Filed: January 24, 2025, 6:59 PM ET

On January 17, 2025, Charles B. O’Keeffe, an independent member of the Board of Directors (“Board”) of Catalyst Pharmaceuticals, Inc. (the “Company”), advised the Company of his decision to not stand for reelection at the 2025 annual meeting of the Company’s stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles B. O’Keeffe departed as Lead Independent Director at CATALYST PHARMACEUTICALS, INC..

Action: retire
Role: Lead Independent Director

Exact text from the filing

On January 17, 2025, Charles B. O’Keeffe, an independent member of the Board of Directors (“Board”) of Catalyst Pharmaceuticals, Inc. (the “Company”), advised the Company of his decision to not stand for reelection at the 2025 annual meeting of the Company’s stockholders.

View on SEC.gov

CATALYST PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-012233

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.